03:54 AM EST, 12/04/2024 (MT Newswires) -- Trevi Therapeutics ( TRVI ) said late Tuesday topline data from a human abuse potential study shows that its oral nalbuphine drug candidate, aimed at the treatment of chronic cough, had statistically significant lower "drug liking" compared with butorphanol.

Drug liking is a measure of the pleasurable experience after consuming a drug, often used to study their misuse liability.

The company added, however, that the supratherapeutic dose of oral nalbuphine at 486 milligrams "was numerically lower" than the 6mg IV butorphanol for drug liking "but the results were not statistically significant."

The study did not observe any serious adverse events, the company said.

Shares of Trevi Therapeutics ( TRVI ) were down more than 13% in after-hours activity Tuesday.